Background: Ataxia telangiectasia mutated (ATM) kinase is a critical regulator in initiating DNA damage response and activating DNA repair. However, the correlation between ATM expression and the outcome of laryngopharyngeal cancer patients is unknown. We hypothesize that ATM expression is correlated with a worse outcome in laryngopharyngeal cancer patients.
introduction
DNA damage response plays an important role in the maintenance of genome integrity. Defects or dysregulation of genes involved in DNA damage response and DNA repair can result in genomic instability, which is a common feature of cancer cells [1] . Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. It has been suggested that genomic instability may be involved in the development of HNSCC [2] [3] [4] . Some studies have shown that DNA repair activity is reduced in the peripheral blood cells of HNSCC patients when compared with normal individuals [5, 6] . These indicate that interference of DNA damage repair may contribute to tumorigenesis of HNSCC. Nevertheless, studies on DNA repair gene expression in head and neck cancers are limited so far.
Ataxia telangiectasia mutated (ATM) kinase is a critical regulator in DNA damage response and is conserved in all eukaryotes from yeast to human. It is activated immediately upon DNA damage and then phosphorylates p53, BRCA1, CHEK1/2, and many others, which lead to activation of DNA repair and cell cycle arrest [7] . Germline mutation of ATM gene results in ataxia telangiectasia, a syndrome susceptible to various cancers. Loss of ATM gene or decreased ATM expression is found in human cancers [8] [9] [10] [11] [12] [13] [14] . Parikh et al. [14] found that the ATM locus was partially lost in 8 of 11 HNSCC cell lines examined and in at least 60% of human malignancies including HNSCC. This partial loss of ATM locus was correlated with a reduced expression of ATM protein level in HNSCC cell lines [14] . In addition, Ai et al. [15] and Bolt et al. [16] have shown hypermethylation of ATM promoter in head and neck cancer, suggesting that ATM expression might be repressed. Indeed, He et al. [10] found an absent or reduced ATM protein expression in 31.25% of oral squamous cell carcinoma, and the patients with reduced/absent ATM expression had poorer differentiated tumor and more lymph node invasion. Bose et al. [8] also showed that ATM messenger RNA (mRNA) and protein were downregulated in Epstein-Barr virus-associated nasopharyngeal carcinoma. However, whether ATM expression is also repressed in HNSCC at larynx and pharynx subsites and whether ATM expression is correlated with HNSCC patient outcome are unclear. In these regards, we examined ATM expression in laryngeal and pharyngeal cancers and correlated ATM expression with clinicopathologic parameters to explore the role of ATM expression in the prediction of patient outcome.
patients and methods subjects
The specimens of 40 laryngeal cancer patients (17 paired tumor and adjacent normal tissues plus 23 tumors only) and 40 pharyngeal cancer patients (15 paired tumor and adjacent normal tissues plus 25 tumors only) were obtained from the Department of Otolaryngology, Kaohsiung Medical University Hospital. These specimens were collected after obtaining patient's informed consent, and the study was approved by the Institutional Review Board. Specimens were snap frozen in liquid nitrogen and were stored at 280°C until use. The age of patients was between 33 and 82 years, with the median of 61 years, the first quartile of 54 years, and the third quartile of 70 years.
RNA isolation, reverse transcription, and real-time quantitative PCR
The method for quantitatively analyzing mRNA expression was as described in our previous paper [17] . Briefly, total RNA was isolated by Tri-reagent (Sigma-Aldrich, St Louis, MO). Reverse transcription was conducted with 1 lg of total RNA and the High-Capacity cDNA Archive Kit (Applied BioSystems, Foster City, CA) in 20 ll. The resulting complementary DNA (cDNA) was subsequently diluted to a total volume of 100 ll and 2 ll of diluted cDNA was used as templates for real-time quantitative PCR (Q-PCR). Q-PCR was carried out in a total volume of 20 ll using PowerSYBR Green reagent (Applied BioSystems) and ABI Prism 7500 Sequence Detection System instrument (Applied BioSystems). The PCR condition was 50°C for 2 min, 95°C for 10 min followed by 50 cycles at 95°C for 15 s and 60°C for 1 min. Dissociation curve was added at the final step to validate that only the specific target was amplified. The PCR primers were designed using the ProbeFinder software (Roche Applied Science, Mannheim, Germany) and were ATM-F: ATAGATTGTGTAGGTTCCGATGG, ATM-R: CATCTTGTCTCAGGTCATCACG; ACTB-F: ATTGGCAATGAGCGGTTC, ACTB-R: GGATGCCACAGGACTCCAT. The ATM mRNA level in each sample was calculated by 2 2DD C T method [18] and ACTB was used as an internal control. Each specimen was examined by at least two independent rounds of reverse transcription and Q-PCR reactions for ATM and internal control. In all cases with paired specimens, the ATM mRNA expression of each case was represented by the ratio of ATM mRNA level in each tumor to that of the corresponding normal part. For the cases with tumor parts only, the mean ATM mRNA levels of all normal tissue specimens were used for comparison with those from each individual tumor.
statistical analyses
The ATM mRNA expressions were categorized into two groups (<0. 3 To examine ATM expression in laryngeal and pharyngeal cancers, we harvested total RNA from 80 surgically resected and previously untreated tumors. The characteristics of patients were shown in Table 1 . The ATM mRNA expression was determined by real-time quantitative RT-PCR using ACTB as an internal control. The results showed that ATM mRNA expression was decreased (tumor/normal <1) in 65 of 80 (81.3%) laryngeal and pharyngeal cancers ( Table 1 ). The median of ATM mRNA expression (tumor/normal) in the 80 cases was 0.364, and the 25% and 75% quartiles were 0.222 and 0.762, respectively ( Figure 1 ). These results demonstrated that ATM mRNA was frequently downregulated in laryngeal and pharyngeal cancers.
ATM mRNA expression is correlated with survival of laryngeal and pharyngeal cancer patients
To explore the possible role of decreased ATM expression in laryngeal and pharyngeal cancers, the correlation between ATM mRNA expression and clinicopathologic features was analyzed. We used the ratio of ATM mRNA expression of tumor versus normal at 0.3 as a cut-off point according to the ReceiverOperating Characteristic curve analysis, by which an association (P = 0.048, Chi-square analysis) between patient survival status and ATM mRNA expression was observed (Table 2 ). Patients (Table 2) .
We next analyzed 3-year and 5-year survival rates using KaplanMeier estimates with log-rank tests. The results demonstrated that patients with age <55 years (P = 0.004), with larger tumor size (T 3 and T 4 , P = 0.012), and with lower ATM mRNA expression (<0.3, P = 0.015) had poorer survival rates (Table 3 ). Figure 2 shows a significant difference in survival rates between individuals with higher and lower ATM mRNA expression. These data indicated that ATM mRNA expression could be a prognostic marker for laryngeal and pharyngeal cancers.
lower ATM mRNA expression is an independent risk factor for survival of laryngeal and pharyngeal cancer patients
To investigate whether lower ATM mRNA expression (<0.3) alone could predict poor outcome of laryngeal and pharyngeal cancers, (Table 4 ). These results indicated that lower ATM mRNA expression could be an independent risk factor for survival of laryngeal and pharyngeal cancer patients. When considering the ratio of ATM mRNA expression itself in the multivariate Cox regression analysis, a trend of association between ATM mRNA expression and overall survival could be found (supplemental Table S1 , available at Annals of Oncology online), although statistical significance was not reached (P = 0.071).
patients with lower ATM expression and younger age or larger tumor size have the poorest outcome
We examined the effect of combining lower ATM mRNA expression with age or tumor size on predicting patient outcome. As shown in Figure 3 , all seven patients in the <55-year-old group who have lower ATM mRNA expression (<0.3) died within 4 years. In addition, a significant proportion (13/16, 81.3%) of patients with lower ATM mRNA expression (<0.3) and larger tumor size (T 3 -T 4 ) died within 3 years. On the contrary, patients with T 1 -T 2 tumors or patients whose age was >55 years in combination with higher ATM mRNA expression ( ‡0.3) had better survival rates ( Figure 3) . Multivariate Cox regression model ( (Figure 1 ), and the lower ATM expression (<0.3) was an independent risk factor for patient's survival (Table 4) . To our knowledge, this is the first study showing that ATM expression is a valuable prognostic marker for HNSCC. It has been demonstrated that ATM expression was repressed in oral and nasopharyngeal carcinomas [8, 10] , but the effect of ATM downregulation on patient's outcome of these two malignancies was not shown. The prognostic role of ATM expression has been demonstrated in other malignancies, including breast [13] , colon [9] , lung [12] , and gastric cancer [11] . All these studies showed that lower ATM expression was a risk factor for patient's outcome, except for that in lung cancer [12] . Given the above, it seems that lower ATM expression is usually correlated with poor outcome of cancer patients. Moreover, we noted that the prognostic value of ATM expression could be largely enhanced by co-evaluating patient's age or tumor size (Table 5 ). Both were also independent risk factors for patient's survival (Table 4) . Early onset of HNSCC implies that these patients may have certain genetic susceptibilities for tumor development. Large tumor size may reflect that the tumor cells have accumulated much more genetic alterations. Therefore, it is reasonable to combine ATM expression with these two independent risk factors as predictive parameters to better estimate the effect. One of the mechanisms underlying the downregulation of ATM mRNA expression may be hypermethylation of the ATM promoter. This results in suppression of promoter activity and has been demonstrated in HNSCC [15, 16] and other malignancies [19] . In this regard, our in vitro study showed that ATM promoter activity could be inhibited by ingredients of betel nut (C.-S. Lin, H.-Y. Hsieh, Y.-S. Tsai and J.-L. Huang, unpublished data), which is a popular substance for habitual use in India and Southeast Asia including Taiwan. However, the relationship between lower ATM expression and the habit of betel quid chewing in HNSCC patients remains to be established. Another mechanism accounting for ATM suppression may be the loss of ATM gene locus, by which reduced copy numbers at chromosome 11q22-23 has been demonstrated in HNSCC by comparative genomic hybridization [3, 20, 21] . In our studied cases, only one tumor specimen showed negative RT-PCR amplification (not included in the 80 cases described), implying that deletion of ATM gene might be possible for this case. However, since ATM mRNA could more or less be detected in all 80 tumors, complete gene deletions could not be the reason. Rather, the possibility of loss of one allele at chromosome 11q22-23 should not be excluded. Indeed, Parikh et al. [14] found that ATM locus was partially lost in 8 of 11 HNSCC cell lines and all five clinical specimens examined. Lazar et al. [22] also showed loss of heterozygosity (LOH) at 11q23 in 25% (13/52) of primary HNSCC. These results support that loss of ATM locus is possibly one of the mechanisms accounting for lower ATM expression found in HNSCC.
In addition to ATM, only a limited number of DNA repair genes have been examined for their expression and prognostic role in head and neck cancers. Excision repair cross complementation group 1 (ERCC1), which removes cisplatininduced DNA adducts, plays an important role in both damage recognition and incision activities of nucleotide excision repair. It has been shown that lower ERCC1 expression was associated with a lower risk of death from advanced head and neck cancer and also benefited from cisplatin induction chemotherapy [23] . This is possibly correlated with the reduced repair of cisplatin-DNA adducts, which in turn leads to lethal DNA strand breaks and facilitates the eradication of tumor cells. On the other hand, the Nijmegen breakage syndrome gene product (NBN) that works together with MRE11A and RAD50 to recognize DNA double-strand breaks and initiate the signaling for DNA repair was shown to be an independent marker of poor prognosis for advanced HNSCC patients when overexpressed [24] . The authors also found that overexpression of NBN could increase cell transformation. These results suggest that the roles of DNA repair gene expressions in predicting patient outcome may be dependent on the characteristics of each gene and the pathways involved.
In the present study, the patients were mostly treated with concurrent chemoradiotherapy after surgical resection. The relationship between ATM expression and patient treatments was not yet explored in detail. However, according to the study of Parikh et al. [14] that partial loss of ATM gene and reduced ATM expression is associated with a reduced sensitivity of HNSCC cells to ionizing irradiation (IR) and the finding of Lazar et al. [22] that LOH at ATM locus in HNSCC is associated with recurrent disease among patients who received radiotherapy, it is proposed that laryngopharyngeal tumors with lower ATM expression may be less responsive to radiotherapy and/or chemotherapy than those with higher ATM expression. As a result, patients with lower ATM mRNA expression may exhibit a poor outcome as shown in this study. This hypothesis suggests that a combination regimen exploiting different cell-killing mechanisms may be superior to monotherapy. Recent results obtained from several clinical trials support this hypothesis, by which another cell-killing mechanism via mitotic catastrophe induced by docetaxel can add the efficacy of chemotherapy using cisplatin and fluorouracil and improve the overall survival rates of patients with no distant metastatic HNSCC [25] [26] [27] . Another trial that combines platinum-based chemotherapy and cetuximab (by antagonizing the signaling of epidermal growth factor receptor) also improves the overall survival of head and neck cancer patients with recurrent or metastatic tumors [28] . Therefore, the concomitant findings of lower ATM expression and reduced IR response may, at least partly, explain why these trials that use combination therapy can improve survival of HNSCC patients.
Recent studies on modulating DNA repair pathways to improve cancer treatments have become an attractive strategy [29] . Tumor cells survived from innumerable genetic alterations depend largely on multiple DNA repair pathways. However, defects of specific DNA repair pathway may arise during tumor development. Inhibition of another DNA repair pathway can therefore increase selectively killing of tumor cells that contain certain alterations of DNA damage response or DNA repair pathway. For example, poly 
